Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve 1. Audited financial results of ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Ltd has notified BSE that a Board Meeting is scheduled for 27 May 2026. The meeting will consider and approve the audited standalone and consolidated financial results for Q4 and FY ended 31 March 2026, along with auditor reports. Additionally, the Board will consider recommending a dividend for FY 2026, appoint Internal Auditors and Cost Auditors for FY 2025-26, and approve grant of stock options to employees under the Bal Pharma Ltd Employee Stock Option Plan - 2025. The trading window for insiders has been closed from 1 April 2026 until 48 hours after the results declaration.
This is a routine regulatory intimation. The actual impact will depend on the financial results to be declared. The stock option plan could have a dilutive effect on equity. Dividend recommendation, if approved, would be positive for shareholders.